How should bullous skin lesions be evaluated and managed in a patient with chronic hepatitis C infection?

Bullous Skin Lesions in Hepatitis C: Evaluation and Management

In a patient with hepatitis C presenting with bullous skin lesions, you must first determine the specific dermatologic diagnosis through skin biopsy with direct immunofluorescence and porphyrin studies, as the management differs fundamentally between autoimmune bullous diseases (bullous pemphigoid, epidermolysis bullosa acquisita, lichen planus) and porphyria cutanea tarda.

Diagnostic Approach

Initial Evaluation Steps

Obtain detailed history focusing on:

• Timing of lesion onset relative to HCV diagnosis or treatment
• Distribution pattern (sun-exposed areas suggest PCT; flexural surfaces suggest BP)
• Presence of scarring, milia formation, or mucosal involvement
• Current or recent medications (especially if on interferon-based therapy)
• Pruritus severity

Physical examination specifics:

• Porphyria cutanea tarda: Vesicles/bullae on sun-exposed areas (dorsal hands, face), skin fragility, hyperpigmentation, hypertrichosis, milia cysts 1, 2, 3
• Bullous pemphigoid: Tense bullae on erythematous base, flexural distribution, severe pruritus, minimal mucosal involvement 4
• Epidermolysis bullosa acquisita: Skin fragility, trauma-induced blistering, scarring with milia 5

Essential Diagnostic Tests

Mandatory investigations:

1. Skin biopsy from early lesion for histopathology (formalin-fixed)
2. Perilesional skin biopsy for direct immunofluorescence (DIF) - critical for autoimmune bullous diseases 6, 7
3. Serum and urine porphyrin panel if PCT suspected 1, 3
4. Serum ferritin and iron studies - elevated in PCT 1, 3
5. HCV viral load and genotype 4

DIF interpretation:

• Linear IgG/C3 at basement membrane zone = bullous pemphigoid 6, 7
• Linear IgG at dermal side of salt-split skin = epidermolysis bullosa acquisita 5
• Negative DIF with elevated porphyrins = porphyria cutanea tarda 1

Management by Diagnosis

Porphyria Cutanea Tarda (Most Common in HCV)

Primary treatment approach:

Iron reduction is essential 1, 3:

• Therapeutic phlebotomy: 450 mL every 2 weeks until ferritin <20 ng/mL
• If anemic (common in HCV patients): Maximize erythropoietin-stimulating agents first to mobilize iron stores, then perform phlebotomy 1
• Target ferritin reduction correlates with lesion improvement

Adjunctive measures:

• Strict photoprotection
• Low-dose chloroquine (125 mg twice weekly) if phlebotomy contraindicated 8
• Avoid alcohol and hepatotoxic medications

HCV treatment considerations:

• Avoid ribavirin-containing regimens - ribavirin causes hemolysis, worsening iron overload and potentially exacerbating PCT 8
• Use interferon-free, ribavirin-free DAA regimens for HCV treatment 8
• Treat HCV after PCT stabilization to avoid complications

Bullous Pemphigoid Associated with HCV

Initial management 6, 7, 4:

Systemic corticosteroids (first-line):

• Prednisolone 0.5-0.75 mg/kg/day (typically 30-40 mg daily for elderly)
• Avoid doses >40 mg daily - associated with significantly higher first-year mortality in elderly patients 6
• Taper gradually after blister control (typically 1-4 weeks)

HCV treatment timing:

• Treat bullous pemphigoid first to achieve skin control 4
• Once stable on minimal corticosteroids, initiate DAA therapy
• Use interferon-free regimens exclusively - interferon can worsen autoimmune phenomena 8

Successful case example: Patient treated with methylprednisolone for BP, followed by sofosbuvir plus ribavirin achieving sustained viral response with skin improvement 4

Lichen Planus (If Bullous Variant)

Critical treatment principle:

• Absolutely avoid interferon-based HCV therapy - type-1 interferons drive lichenoid inflammation and will worsen or trigger lichen planus 8
• Use topical corticosteroids for localized disease
• Systemic therapy (acitretin, methotrexate, cyclosporine) for severe disease with careful monitoring of liver function 8
• Treat with DAA regimens only after LP controlled

HCV Treatment Selection

Based on 2017 KASL guidelines 9:

For genotype-specific treatment (once dermatologic condition stable):

Genotype 1a 9:

• Ledipasvir/sofosbuvir 12 weeks (A1)
• Glecaprevir/pibrentasvir 8 weeks (non-cirrhotic) or 12 weeks (cirrhotic) (A1)
• Sofosbuvir/velpatasvir 12 weeks (A1)

Genotype 2 9:

• Glecaprevir/pibrentasvir 8 weeks (non-cirrhotic) or 12 weeks (cirrhotic) (A1)
• Sofosbuvir/velpatasvir 12 weeks (A1)

Genotype 3 9:

• Glecaprevir/pibrentasvir 8 weeks (non-cirrhotic) or 12 weeks (cirrhotic)
• Sofosbuvir/velpatasvir 12 weeks

Genotype 4 9:

• Ledipasvir/sofosbuvir 12 weeks (A1)
• Glecaprevir/pibrentasvir 8-12 weeks (A1)
• Sofosbuvir/velpatasvir 12 weeks (A1)

Critical Pitfalls to Avoid

1. Never use interferon-based therapy in patients with autoimmune bullous diseases or lichen planus - will exacerbate condition 8

2. Avoid ribavirin in PCT - hemolytic anemia worsens iron overload 8

3. Do not delay skin biopsy with DIF - essential for distinguishing autoimmune from metabolic causes 6, 7

4. Do not use high-dose corticosteroids (>40 mg prednisolone) in elderly BP patients - doubles mortality risk 6

5. Check for drug-drug interactions between DAAs and immunosuppressants (especially cyclosporine) 8

6. Monitor for HBV reactivation if anti-HBc positive before starting DAA therapy 10

Monitoring During Treatment

• Weekly assessment during initial corticosteroid therapy for BP
• Ferritin levels every 2-4 weeks during phlebotomy for PCT
• HCV viral load at week 4 and 12 of DAA therapy, then 12 weeks post-treatment for SVR
• Liver function tests every 4 weeks during immunosuppressive therapy 8